These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 20335450)
1. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. Fougner SL; Lekva T; Borota OC; Hald JK; Bollerslev J; Berg JP J Clin Endocrinol Metab; 2010 May; 95(5):2334-42. PubMed ID: 20335450 [TBL] [Abstract][Full Text] [Related]
2. Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. Elston MS; Gill AJ; Conaglen JV; Clarkson A; Cook RJ; Little NS; Robinson BG; Clifton-Bligh RJ; McDonald KL J Clin Endocrinol Metab; 2009 Apr; 94(4):1436-42. PubMed ID: 19158195 [TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly. Lekva T; Berg JP; Fougner SL; Olstad OK; Ueland T; Bollerslev J J Clin Endocrinol Metab; 2012 Aug; 97(8):E1506-14. PubMed ID: 22585092 [TBL] [Abstract][Full Text] [Related]
4. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Fougner SL; Casar-Borota O; Heck A; Berg JP; Bollerslev J Clin Endocrinol (Oxf); 2012 Jan; 76(1):96-102. PubMed ID: 21722151 [TBL] [Abstract][Full Text] [Related]
5. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness. Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216 [TBL] [Abstract][Full Text] [Related]
6. Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly. Mendes GA; Haag T; Trott G; Rech CGSL; Ferreira NP; Oliveira MC; Kohek MB; Pereira-Lima JFS Braz J Med Biol Res; 2017 Dec; 51(2):e6808. PubMed ID: 29267504 [TBL] [Abstract][Full Text] [Related]
7. [Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry]. Jaquet P; Cortet-Rudelli Ch; Sassolas G; Morange-Ramos I; Chanson P; Brue T; Andrieu JM; Beckers A; Bertherat J; Borson-Chazot F; Brassier G; Caron P; Cogne M; Cottier JP; Delemer B; Dufour H; Enjalbert A; Figarella-Branger D; Gaillard R; Gueydan M; Jan M; Kuhn JM; Raingeard I; Regis J; Roger P; Rohmer V; Sadoul JL; Saveanu A; Tabarin A; Travers N; Trouillas J; Ann Endocrinol (Paris); 2003 Dec; 64(6):434-41. PubMed ID: 15067248 [TBL] [Abstract][Full Text] [Related]
8. E-cadherin expression is associated with somatostatin analogue response in acromegaly. Venegas-Moreno E; Flores-Martinez A; Dios E; Vazquez-Borrego MC; Ibañez-Costa A; Madrazo-Atutxa A; Japón MA; Castaño JP; Luque RM; Cano DA; Soto-Moreno A J Cell Mol Med; 2019 May; 23(5):3088-3096. PubMed ID: 30843342 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202 [TBL] [Abstract][Full Text] [Related]
10. [Outcome of somatostatin analogue treatment in acromegaly]. Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182 [TBL] [Abstract][Full Text] [Related]
11. Octreotide as primary therapy for acromegaly. Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397 [TBL] [Abstract][Full Text] [Related]
12. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas. Lekva T; Berg JP; Lyle R; Heck A; Ringstad G; Olstad OK; Michelsen AE; Casar-Borota O; Bollerslev J; Ueland T Endocrinology; 2013 Sep; 154(9):3331-43. PubMed ID: 23825128 [TBL] [Abstract][Full Text] [Related]
13. Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery. Lekva T; Berg JP; Heck A; Lyngvi Fougner S; Olstad OK; Ringstad G; Bollerslev J; Ueland T PLoS One; 2013; 8(6):e66927. PubMed ID: 23825587 [TBL] [Abstract][Full Text] [Related]
14. CCNB1 affects cavernous sinus invasion in pituitary adenomas through the epithelial-mesenchymal transition. Li B; Cheng J; Wang H; Zhao S; Zhu H; Li C; Zhang Y; Zhao P J Transl Med; 2019 Oct; 17(1):336. PubMed ID: 31585531 [TBL] [Abstract][Full Text] [Related]
15. Alternative splicing of placental lactogen (CSH2) in somatotroph pituitary adenomas. Lekva T; Berg JP; Lyle R; Heck A; Bollerslev J; Ueland T Neuro Endocrinol Lett; 2015; 36(2):136-42. PubMed ID: 26071582 [TBL] [Abstract][Full Text] [Related]
16. Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas. Nishioka H; Haraoka J; Akada K Clin Endocrinol (Oxf); 2003 Dec; 59(6):768-72. PubMed ID: 14974920 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Xu B; Sano T; Yoshimoto K; Yamada S Endocr Pathol; 2002; 13(4):341-51. PubMed ID: 12665652 [TBL] [Abstract][Full Text] [Related]
18. Expression of epithelial cadherin and cavernous sinus invasion in human pituitary adenomas. Kawamoto H; Mizoue T; Arita K; Tominaga A; Eguchi K; Kurisu K J Neurooncol; 1997 Sep; 34(2):105-9. PubMed ID: 9210056 [TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382 [TBL] [Abstract][Full Text] [Related]